Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInterest Coverage RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on EquityTimes Interest Earned

CNBX Pharmaceuticals (CNBX) FCF Margin (2016 - 2024)

CNBX Pharmaceuticals (CNBX) has disclosed FCF Margin for 11 consecutive years, with 306.12% as the latest value for Q1 2024.

  • For the quarter ending Q1 2024, FCF Margin changed N/A year-over-year to 306.12%, compared with a TTM value of 520.46% through Nov 2024, down 50252.0%, and an annual FY2024 reading of 188.71%, down 16128.0% over the prior year.
  • FCF Margin was 306.12% for Q1 2024 at CNBX Pharmaceuticals, down from 81.67% in the prior quarter.
  • Across five years, FCF Margin topped out at 804.7% in Q2 2022 and bottomed at 55628.24% in Q1 2020.
  • Average FCF Margin over 4 years is 13533.26%, with a median of 306.12% recorded in 2024.
  • Peak annual rise in FCF Margin hit 1121676bps in 2020, while the deepest fall reached -2202764bps in 2020.
  • Year by year, FCF Margin stood at 32350.93% in 2020, then soared by 98bps to 502.88% in 2022, then skyrocketed by 84bps to 81.67% in 2023, then tumbled by -275bps to 306.12% in 2024.
  • Business Quant data shows FCF Margin for CNBX at 306.12% in Q1 2024, 81.67% in Q4 2023, and 20.52% in Q3 2023.